209 related articles for article (PubMed ID: 18519772)
1. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.
Wei LH; Su H; Hildebrandt IJ; Phelps ME; Czernin J; Weber WA
Clin Cancer Res; 2008 Jun; 14(11):3416-26. PubMed ID: 18519772
[TBL] [Abstract][Full Text] [Related]
2. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Ma WW; Jacene H; Song D; Vilardell F; Messersmith WA; Laheru D; Wahl R; Endres C; Jimeno A; Pomper MG; Hidalgo M
J Clin Oncol; 2009 Jun; 27(16):2697-704. PubMed ID: 19380450
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
Brepoels L; Stroobants S; Verhoef G; De Groot T; Mortelmans L; De Wolf-Peeters C
J Nucl Med; 2009 Jul; 50(7):1102-9. PubMed ID: 19525456
[TBL] [Abstract][Full Text] [Related]
4. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
[TBL] [Abstract][Full Text] [Related]
5. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer.
von Forstner C; Egberts JH; Ammerpohl O; Niedzielska D; Buchert R; Mikecz P; Schumacher U; Peldschus K; Adam G; Pilarsky C; Grutzmann R; Kalthoff H; Henze E; Brenner W
J Nucl Med; 2008 Aug; 49(8):1362-70. PubMed ID: 18632830
[TBL] [Abstract][Full Text] [Related]
6. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
7. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
Li Z; Graf N; Herrmann K; Jünger A; Aichler M; Feuchtinger A; Baumgart A; Walch A; Peschel C; Schwaiger M; Buck A; Keller U; Dechow T
Cancer Res; 2012 Oct; 72(19):5014-24. PubMed ID: 22875026
[TBL] [Abstract][Full Text] [Related]
8. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
9. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
[TBL] [Abstract][Full Text] [Related]
10. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
11. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
12. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
[TBL] [Abstract][Full Text] [Related]
13. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
[TBL] [Abstract][Full Text] [Related]
14. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
[TBL] [Abstract][Full Text] [Related]
15. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice.
Murayama C; Harada N; Kakiuchi T; Fukumoto D; Kamijo A; Kawaguchi AT; Tsukada H
J Nucl Med; 2009 Feb; 50(2):290-5. PubMed ID: 19164228
[TBL] [Abstract][Full Text] [Related]
17. The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma.
Xu X; Xu J; Knutsson L; Liu J; Liu H; Li Y; Lal B; Laterra J; Artemov D; Liu G; van Zijl PCM; Chan KWY
Magn Reson Med; 2019 Jun; 81(6):3798-3807. PubMed ID: 30793789
[TBL] [Abstract][Full Text] [Related]
18. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Kelly CJ; Hussien K; Muschel RJ
Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
[TBL] [Abstract][Full Text] [Related]
19. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
